On the use of list prices in drug pricing research

Health Affairs Blog

14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture manufacturer rebates or other discounts, which could have led to the overestimation of the contribution of existing drugs in rising prices.

In a recent Health Affairs Blog post, Dr. Robert Dubois, Chief Science Officer and Executive Vice-president of the National Pharmaceutical Council, critiques our use of list price data and suggests that our analyses could have accounted for rebates through the use of SSR Health or IQVIA data. 

We have discussed with both SSR Health and IQVIA how their data can be applied in drug pricing research, and we confirmed that neither of them contain complete rebate information at the drug level.

Read Health Affairs blog

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Pricing , Publication , Research